AnGes

FY2026-3Q Financial Results Materials

November 2026

Major Business Highlights for FY2026-3Q

【HGF Gene Therapy Product】：Preparing for BLA in the US

US：Preparing for Biologics License Application (BLA)

Rolling Submission (initial document submission) scheduled to begin in Q4

→Preparation in coordination with the FDA

JP：Future actions are under consideration based on progress in the US

【NF-κB Decoy Oligonucleotide DNA】：P2Clinical Trial Ongoing in Japan

Results from the P1 clinical trial in the US were published in *The SPINE Journal*, the official journal of the North American Spine Society.

→Aiming to complete registration of the planned number of cases by fiscal year 2026

【Tie2 Receptor Agonist】：Completion of Phase 2 clinical trial registration for ARDS in the US

Completed patient enrollment for the Phase 2 clinical trial in the United States

→ Preliminary test results are expected to be released in Q1 2027

Progress in Physician-Initiated Trial Evaluating Reduction of Cognitive Impairment in Hemodialysis Patients

Secured support from the National Research Organization of Canada Industrial Technology Support Program for subcutaneous injection formulation development

Major Business Highlights for FY2026-3Q

【Zokinvy】：Revising Sales Outlook

【ACRL】：Contracting for expanded newborn screening remains stable

- Expanded Newborn Screening
  The number of contracted diseases has expanded from 9 to 14, and the number of contracts has remained stable
- Establishment of a Comprehensive Testing Framework
  Expanding the range of diseases covered by genetic testing
  →In addition to HGPS and PDPL, seven diseases have been added to the expanded newborn screening target
  Research Utilizing Biomarker Testing for Secondary Screening Published

【EmendoBio】：Promoting research and business development of OMNI nuclease

Establishing a system to advance research and development activities and exports in the US

Promoting joint research with Stanford University on new cancer genomic therapies

Considering opening a new research and development center in the US

Anocca's license revenue is expected to shift to next fiscal year

Performance for FY2026-3Q

Although business revenue increased, business expenses increased due to HGF application preparation costs

(Unit：Million Yen)

	FY2025-1Q	FY2026-1Q	Change
Revenue	646	**751**	104
Operating Expenses	4,188	**5,776**	1,587
Operating Profit(Loss)	-3,542	**-5,025**	-1,482
Non Operating Income(Expenses)	-1,073	**92**	1,166
Ordinary Profit(Loss)	-4,615	**-4,932**	-316
Extraordinary Income(Expenses)	0	**-25**	-25
Net Profit(Loss)	-4,688	**-5,081**	-392

Revenue（YoY +16.2%）

- Zokinvi's sales of 328 million yen (YoY +51.6%)
- Screening tests at ACRL amounted to 422 million yen (YoY +2.2%)

Operating Expenses（YoY +37.9%）

- Cost of Sales: 388 million yen (YoY +1 million yen)
  Rising cost of goods sold at Zokinvi
- Research and development expenses: 3,870 million yen (YoY +1,495 million yen)
  Mainly the increase in costs related to preparing HGF applications
- SG&A expenses: 1,517 million yen (YoY +91 million yen)
  Mainly increased financing-related expenses

Non Operating Income

- Foreign exchange gain of 165 million yen from revaluation of loans to EmendoBio

Special Gains and Losses

- Profit from investment securities sales: 11 million yen
- Impairment of EmendoBio Right-of-Use Assets Decreased by 41 million yen

Consolidated Balance Sheet Highlights

(Unit：Million Yen)

	Dec-2025	September-2026	Change
Current Assets	4,386	**2,470**	-1,915
Cash and Deposits	1,882	**233**	-1,648
Non-Current Assets	1,019	**1,001**	-17
Total Assets	5,405	**3,472**	-1,933
Liabilities	2,329	**4,830**	2,500
Net Assets	3,076	**-1,357**	-4,433

Curent Assets

531 million yen through the 46th stock acquisition rights
647 million yen through bond issuance
241 million yen through the 47th and 48th stock acquisition rights
2,000 million yen through bonds with stock acquisition rights
Raised 100 million yen through borrowings
Due to expenditures on business expenses, etc.: -1,648 million yen

Net Assets

By exercising the 46th and 47th stock acquisition rights
Capital stock and capital surplus each increased by +380 million yen
Net assets decreased by 5,081 million yen due to quarterly net loss

Revision of the FY2026 earnings outlook

(Unit：Million Yen)

	Revenue	Operating Profit/Loss	Ordinary Profit/Loss	Net Profit/Loss
FY2026 Revised plan	**1,000**	**-8,900**	**-9,000**	**-9,100**
FY2026 Initial Plan	1,330	-10,230	-10,240	-10,250
increase or decrease	-330	1,330	1,240	1,150

Business revenue declined due to the following factors:
- Revenue from EmendoBio's licensing is expected to be pushed forward to next fiscal year
- Sales outlook for Zokinvy decreased compared to the initial plan

Various profits and losses improved due to the following factors:
- Thorough cost reduction for both R&D and SG&A expenses, and review implementation timing

Genetic Innovation for All

https://www.anges.co.jp/en